{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T18:29:15Z","timestamp":1777919355089,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2008,3,26]],"date-time":"2008-03-26T00:00:00Z","timestamp":1206489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2008,3,26]],"date-time":"2008-03-26T00:00:00Z","timestamp":1206489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuroendocrinology"],"abstract":"<jats:p>Neurotensin (NT) when injected in a dose of 5 \u03bcg into the third cerebral ventricle of conscious, unrestrained male rats, outfitted with chronic third ventricle and jugular cannulae, decreased the resting prolactin (PRL) levels. NT (5 \u03bcg) also markedly inhibited the PRL-releasing effect of activation of central serotonin receptors by 5-hydroxytryptophan (5HTP, 15 mg\/kg) in animals pretreated with fluoxetine (4 mg\/kg). however, interruption of dopamine (DA) neurotransmission by either \u03b1-methyl-p-tyrosine (\u03b1MT, 250 mg\/kg) or spiroperidol (0.3 mg\/kg) led to a blockade of the PRL-inhibit-ing effect of NT. Treatment of animal with \u03b1MT prior to the injection of fluoxetine and 5HTP also blocked the PRL-inhibiting effect of NT. These results suggest that the central dopaminergic system mediates the PRL-inhibitory effect of NT.<\/jats:p>","DOI":"10.1159\/000123394","type":"journal-article","created":{"date-parts":[[2008,3,26]],"date-time":"2008-03-26T11:20:14Z","timestamp":1206530414000},"page":"277-281","source":"Crossref","is-referenced-by-count":18,"title":["On the Prolactin-Inhibiting Effect of Neurotensin"],"prefix":"10.1159","author":[{"given":"J.I.","family":"Koenig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Mayfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.M.","family":"McCann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Krulich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2008,3,26]]},"container-title":["Neuroendocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/123394","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000123394","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T19:00:54Z","timestamp":1777662054000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000123394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,26]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000123394","archive":["Portico"],"relation":{},"ISSN":["0028-3835","1423-0194"],"issn-type":[{"value":"0028-3835","type":"print"},{"value":"1423-0194","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,26]]}}}